BAY-Y-5959

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526903

CAS#: 146136-94-9

Description: BAY-Y-5959 is a calcium channel agonist potentially for the treatment of arrhythmia, heart failure and myocardial.

Chemical Structure

img
BAY-Y-5959
CAS# 146136-94-9
Instruction

Theoretical Analysis

MedKoo Cat#: 526903
Name: BAY-Y-5959
CAS#: 146136-94-9
Chemical Formula: C26H24N4O2
Exact Mass: 424.19
Molecular Weight: 424.504
Elemental Analysis: C, 73.56; H, 5.70; N, 13.20; O, 7.54

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: BAY-Y-5959; BAY-Y5959; BAY-Y 5959; BAYY-5959; BAYY5959; BAYY 5959.

IUPAC/Chemical Name: isopropyl (R)-2-amino-5-cyano-6-methyl-4-(3-phenylquinolin-5-yl)-1,4-dihydropyridine-3-carboxylate

InChi Key: PHJVBZVDUNTGNR-HSZRJFAPSA-N

InChi Code: InChI=1S/C26H24N4O2/c1-15(2)32-26(31)24-23(21(13-27)16(3)30-25(24)28)19-10-7-11-22-20(19)12-18(14-29-22)17-8-5-4-6-9-17/h4-12,14-15,23,30H,28H2,1-3H3/t23-/m1/s1

SMILES Code: O=C(OC(C)C)C1=C(N)NC(C)=C(C#N)[C@H]1C2=CC=CC(N=C3)=C2C=C3C4=CC=CC=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 424.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: de Haan S, Greiser M, Harks E, Blaauw Y, van Hunnik A, Verheule S, Allessie M, Schotten U. AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation. 2006 Sep 19;114(12):1234-42. Epub 2006 Aug 28. PubMed PMID: 16940189.

2: Takagi G, Asai K, Vatner SF, Kudej RK, Rossi F, Peppas A, Takagi I, Resuello RR, Natividad F, Shen YT, Vatner DE. Gender differences on the effects of aging on cardiac and peripheral adrenergic stimulation in old conscious monkeys. Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H527-34. PubMed PMID: 12860563.

3: Schotten U, Duytschaever M, Ausma J, Eijsbouts S, Neuberger HR, Allessie M. Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand. Circulation. 2003 Mar 18;107(10):1433-9. PubMed PMID: 12642366.

4: Cabo C, Schmitt H, Wit AL. New mechanism of antiarrhythmic drug action: increasing L-type calcium current prevents reentrant ventricular tachycardia in the infarcted canine heart. Circulation. 2000 Nov 7;102(19):2417-25. PubMed PMID: 11067798.

5: Pu J, Ruffy F, Boyden PA. Effects of Bay Y5959 on Ca2+ currents and intracellular Ca2+ in cells that have survived in the epicardial border of the infarcted canine heart. J Cardiovasc Pharmacol. 1999 Jun;33(6):929-37. PubMed PMID: 10367597.

6: Asai K, Uechi M, Sato N, Shen W, Meguro T, Mathier MA, Shannon RP, Vatner SF. Lack of desensitization and enhanced efficiency of calcium channel promoter in conscious dogs with heart failure. Am J Physiol. 1998 Dec;275(6 Pt 2):H2219-26. PubMed PMID: 9843822.

7: Uechi M, Asai K, Sato N, Vatner SF. Voltage-dependent calcium channel promoter restores baroreflex sensitivity in conscious dogs with heart failure. Circulation. 1998 Sep 29;98(13):1342-7. PubMed PMID: 9751685.

8: Yi GH, Burkhoff D, Zhang H, Zhu SM, Zwas D, Wang J. Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug;286(2):760-6. PubMed PMID: 9694931.

9: Todaka K, Wang J, Yi GH, Gu A, Zhu SM, Zhang H, Burkhoff D. Effect of BAY y 5959 on myocardial function and metabolism in normal and failing hearts. Am J Physiol. 1998 May;274(5 Pt 2):H1560-8. PubMed PMID: 9612364.

10: Todaka K, Ogino K, Gu A, Burkhoff D. Effect of ventricular stretch on contractile strength, calcium transient, and cAMP in intact canine hearts. Am J Physiol. 1998 Mar;274(3 Pt 2):H990-1000. PubMed PMID: 9530213.

11: Rousseau MF, Massart PE, van Eyll C, Etienne J, Ahn S, Schaefer HG, Mueck W, Bornemann M, Pouleur H. Dose-related hemodynamic and electrocardiographic effects of the calcium promoter BAY y 5959 in the presence or absence of congestive heart failure. J Am Coll Cardiol. 1997 Dec;30(7):1751-7. PubMed PMID: 9385903.

12: Sato N, Uechi M, Asai K, Patrick T, Kudej RK, Vatner SF. Effects of a novel inotropic agent, BAY y 5959, in conscious dogs: comparison with dobutamine and milrinone. Am J Physiol. 1997 Feb;272(2 Pt 2):H753-9. PubMed PMID: 9124435.

13: Bechem M, Goldmann S, Gross R, Hallermann S, Hebisch S, Hütter J, Rounding HP, Schramm M, Stoltefuss J, Straub A. A new type of Ca-channel modulation by a novel class of 1,4-dihydropyridines. Life Sci. 1997;60(2):107-18. PubMed PMID: 9000116.